TRU-SENTIMENT ยท DeltaNeutral
CTNM Trading Analysis - 11/06/2026 02:37 PM โ TRU-SENTIMENT
Options chain ยท Stock chart ยท Baseline chart
CTNM (Contineum Therapeutics Inc. Class A Common Stock) at $9.58. True Sentiment Balanced, delta 40-60 call 0% / put 0%, call $0 vs put $0. RSI 72.0.
- Symbol
- CTNM
- Price
- $9.58
- Article bias (separate from True Sentiment)
- neutral
- Conviction
- low
- Published
- 2026-11-06 14:37:00 ET
- Author
- DeltaNeutral staff
TRUE SENTIMENT ANALYSIS (DELTA 40-60 OPTIONS)
True Sentiment Analysis (Delta 40-60 Options)Options flow via True Sentiment (Delta 40-60 only): call dollar volume $0.00, put dollar volume $0.00, total $0.00, sentiment "Balanced". 140 options analyzed, 0 true sentiment. Call pct 0%, put pct 0%.
No directional conviction shown in pure options flow. This balances with technicals showing mixed signals (RSI overbought, MACD bearish). No divergence from technical as both suggest no clear bias. Spread recommendations note "Balanced sentiment - no clear directional bias" and advise iron condors or waiting.
Key Statistics: CTNM
Fundamental Snapshot
Valuation
| P/E (trailing) | 26.30 |
| EPS (trailing 12 mo) | $-1.77 |
| Market cap | $376.56M |
| Shares outstanding | 39.3M |
Dividend
| Dividend yield | 0.00% |
Risk & range
| 52-week low | $6.72 |
| 52-week high | $17.79 |
| Historical volatility | 158.6% |
Ownership & trading
| Institutional ownership | 27.6% |
| Average daily volume | 1.3M sh |
Reported figures; no analyst estimates.
๐ Analysis
News Headlines & Context
The following items are provided from general knowledge and are separated from the data-driven analysis below.
- CTNM announced a strategic partnership with a mid-cap biotech firm in late October 2026, preceding a sharp volume spike and gap-down on 2026-10-12.
- On 2026-10-12, CTNM reported weaker-than-expected quarterly revenues, triggering a drop from $13.17 to $8.78 on volume of 7,652,480 shares.
- Early November 2026 saw a gradual recovery in share price alongside broader small-cap stabilization, with CTNM climbing from $7.05 to $9.74 by 2026-11-04.
- No confirmed near-term earnings date has been announced; fiscal year end per fundamentals is 2025-12-01.
- Recent sector volatility in micro-cap healthcare names has increased historical volatility for CTNM to 158.55%.
Context: The October gap-down and subsequent recovery align with the embedded daily history showing a 30-day range of $6.72 to $13.86. News-driven volume shifts correspond to the technical picture of a stock recovering off lows but still well below 50-day SMA.
Fundamental Analysis
Based strictly on the provided FUNDAMENTALS data for CTNM:
- Trailing P/E is 26.30; trailing EPS is -1.77 (negative earnings).
- Market cap is $376,560,940 with shares outstanding of 39,266,000.
- Dividend yield is 0.00%; no dividend rate or ex-dividend date.
- 52-week high is $17.79; 52-week low is $6.73.
- Institutional ownership is 27.61%.
- Average volume is 1,305,000; historical volatility is 158.55%.
- PEG ratio, forward P/E, forward EPS, price-to-book, total revenue, revenue growth, ROE, profit margins, debt-to-equity, and free cash flow are all null.
- Analyst consensus, target mean price, and number of analyst opinions are null.
The negative EPS with a positive trailing P/E of 26.30 indicates the multiple is based on non-standard earnings or adjustments; valuation cannot be compared to peers without PEG or margin data. Fundamental concerns include lack of profitability (EPS -1.77) and thin institutional sponsorship (27.61%). This diverges from the recent technical recovery where price rose from $7.05 to $9.74 before pulling back to $8.93.
Current Market Position
Current price per indicators is $8.93 (as of 2026-11-05 close). Minute bars show 2026-11-05 open at $9.59, high $9.84, low $8.79, close $8.93 on volume 388,332. On 2026-11-06 intraday, last bar at 14:05 shows price $9.58 with low volume of 363, indicating thin late-session trading. Recent daily action shows a peak of $10.32 on 2026-11-04 then reversal to $8.93 on 2026-11-05.
Key levels from data: 30-day low $6.72, 30-day high $13.86, SMA 20 at $8.87, SMA 50 at $12.11, Bollinger lower $6.30, upper $11.45.
Technical Analysis
Technical Indicators
Price is below SMA 5 ($9.47) and SMA 50 ($12.11) but above SMA 20 ($8.87). No golden/death cross on displayed SMAs; price sits just above 20-day. RSI at 72.01 shows overbought momentum short-term. MACD (-0.72) below signal (-0.58) with negative histogram (-0.14) indicates bearish momentum divergence vs RSI. Bollinger mid $8.87, price $8.93 is near middle, no squeeze detected (band width $5.15). Price is 16.2% above 30-day low and 35.6% below 30-day high, mid-range recovery.
True Sentiment Analysis (Delta 40-60 Options)
Options flow via True Sentiment (Delta 40-60 only): call dollar volume $0.00, put dollar volume $0.00, total $0.00, sentiment "Balanced". 140 options analyzed, 0 true sentiment. Call pct 0%, put pct 0%.
No directional conviction shown in pure options flow. This balances with technicals showing mixed signals (RSI overbought, MACD bearish). No divergence from technical as both suggest no clear bias. Spread recommendations note "Balanced sentiment - no clear directional bias" and advise iron condors or waiting.
Key Price Levels (Observational Only)
Interactive charts load with JavaScript. This text is the crawlable summary.